(Q42990208)

English

The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.

scientific article published on February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Richard K Sterling

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Robert S Brown

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Charlotte M Hofmann

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Velimir A Luketic

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

R Todd Stravitz

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Arun J Sanyal

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Melissa J Contos

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A Scott Mills

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Vernon Smith

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mitchell L Shiffman

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

313-321

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Hepatitis C in state correctional facilities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

A survey of bloodborne viruses and associated risk behaviours in Greek prisons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Hepatitis C and the correctional population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Which patients with hepatitis C develop liver complications?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Costs of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Treatment of patients with hepatitis C and normal serum aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Treatment of chronic hepatitis C in a state correctional facility

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40116.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2005.40116.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42990208&oldid=1591619188"